scholarly journals Identification of the high-risk group for metastasis of gastric cancer cases by vascular endothelial growth factor receptor-1 overexpression in peripheral blood

2007 ◽  
Vol 96 (11) ◽  
pp. 1723-1728 ◽  
Author(s):  
Y Kosaka ◽  
K Mimori ◽  
T Fukagawa ◽  
K Ishikawa ◽  
T Etoh ◽  
...  
Blood ◽  
2005 ◽  
Vol 106 (7) ◽  
pp. 2347-2355 ◽  
Author(s):  
Elzafir Elsheikh ◽  
Mehmet Uzunel ◽  
Zhong He ◽  
Jan Holgersson ◽  
Grzegorz Nowak ◽  
...  

Abstract The monocyte population in blood is considered a possible source of endothelial precursors. Because endothelial-specific receptor tyrosine kinases act as regulators of endothelial cell function, we investigated whether expression of the vascular endothelial growth factor receptor-2 (VEGFR-2) on monocytes is important for their endothelial-like functional capacity. Peripheral-blood monocytes expressing vascular endothelial growth factor receptor-2 (VEGFR-2), or CD14+/VEGFR-2+, were isolated, and their phenotypic, morphologic, and functional capacities were compared with those of monocytes negative for this marker (CD14+/VEGFR-2-). CD14+/VEGFR-2+ cells constituted approximately 2% ± 0.5% of the total population of monocytes and 0.08% ± 0.04% of mononuclear cells in blood. CD14+/VEGFR-2+ cells exhibited the potential to differentiate in vitro into cells with endothelial characteristics. The cells were efficiently transduced by a lentiviral vector driving expression of the green fluorescence protein (GFP). Transplantation of GFP-transduced cells into balloon-injured femoral arteries of nude mice significantly contributed to efficient reendothelialization. CD14+/VEGFR-2- did not exhibit any of these characteristics. These data demonstrate that the expression of VEGFR-2 on peripheral blood monocytes is essential for their endothelial-like functional capacity and support the notion of a common precursor for monocytic and endothelial cell lineage. Our results help clarify which subpopulations may restore damaged endothelium and may participate in the maintenance of vascular homeostasis.


2016 ◽  
Vol 9 (2) ◽  
pp. 317-320 ◽  
Author(s):  
Michael E. Christiansen ◽  
Timothy Ingall ◽  
Edward C. Lew ◽  
Ramesh K. Ramanathan ◽  
Harshita R. Paripati

Ramucirumab is an antiangiogenesis agent targeting the vascular endothelial growth factor receptor-2 (VEGFR-2), approved to treat advanced gastric and colon cancer. In clinical trials, it was shown to cause a small increase in arterial thromboembolism compared to placebo, including cerebral and myocardial ischemia, which was not statistically significant. Detailed case reports are lacking and we here present one of the first case reports of stroke secondary to ramucirumab-induced in situ thrombosis.


Sign in / Sign up

Export Citation Format

Share Document